Clinical Trial Update: A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease [Phase 2]

View source ↗

Summary

Phase 2 study evaluating MZE829 in adults with APOL1-associated kidney disease; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Apol1-associated Nephropathy
• Chronic Kidney Disease

Drugs mentioned

• MZE829

Snippet

Sponsor: Maze Therapeutics | Conditions: Proteinuric Kidney Disease | Phase 2 | Status: RECRUITING